 Nathan Dahl
Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 11 | 2026 | 426 | 3.560 |
Why?
| | Brain Neoplasms | 8 | 2025 | 1322 | 1.640 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2025 | 1462 | 1.450 |
Why?
| | Brain Stem Neoplasms | 3 | 2023 | 87 | 1.390 |
Why?
| | Cerebellar Neoplasms | 4 | 2025 | 177 | 1.320 |
Why?
| | Medulloblastoma | 4 | 2025 | 215 | 1.300 |
Why?
| | Proto-Oncogene Proteins c-myc | 4 | 2025 | 167 | 1.130 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.840 |
Why?
| | Adrenoleukodystrophy | 1 | 2024 | 8 | 0.830 |
Why?
| | Astrocytoma | 2 | 2024 | 129 | 0.810 |
Why?
| | Transcription, Genetic | 3 | 2025 | 1496 | 0.740 |
Why?
| | Pyrimidinones | 1 | 2023 | 126 | 0.720 |
Why?
| | Adenomatous Polyposis Coli | 2 | 2019 | 40 | 0.700 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.680 |
Why?
| | Pyridones | 1 | 2023 | 199 | 0.670 |
Why?
| | Receptor, trkB | 1 | 2021 | 36 | 0.660 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 64 | 0.640 |
Why?
| | Genes, APC | 2 | 2019 | 11 | 0.640 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 39 | 0.620 |
Why?
| | beta Catenin | 2 | 2019 | 253 | 0.610 |
Why?
| | Histones | 3 | 2026 | 670 | 0.610 |
Why?
| | Oncologists | 1 | 2020 | 46 | 0.600 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 175 | 0.590 |
Why?
| | Bevacizumab | 1 | 2019 | 167 | 0.570 |
Why?
| | Radiotherapy | 1 | 2019 | 206 | 0.550 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 496 | 0.550 |
Why?
| | Craniopharyngioma | 1 | 2019 | 77 | 0.550 |
Why?
| | Brain Diseases | 1 | 2019 | 153 | 0.540 |
Why?
| | Radiation Injuries | 1 | 2019 | 151 | 0.540 |
Why?
| | Chromatin | 5 | 2026 | 561 | 0.530 |
Why?
| | Angiogenesis Inhibitors | 1 | 2019 | 237 | 0.530 |
Why?
| | Mutation | 6 | 2026 | 4099 | 0.520 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 190 | 0.520 |
Why?
| | Chordoma | 1 | 2017 | 17 | 0.510 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 174 | 0.510 |
Why?
| | Skull Base Neoplasms | 1 | 2017 | 30 | 0.510 |
Why?
| | Tuberous Sclerosis | 1 | 2017 | 56 | 0.490 |
Why?
| | Gardner Syndrome | 1 | 2016 | 2 | 0.490 |
Why?
| | Fibroma | 1 | 2016 | 20 | 0.480 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2015 | 22 | 0.460 |
Why?
| | Chromosome Deletion | 1 | 2015 | 124 | 0.450 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 105 | 0.440 |
Why?
| | Niacinamide | 1 | 2015 | 86 | 0.440 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2025 | 930 | 0.440 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 112 | 0.440 |
Why?
| | Azacitidine | 1 | 2015 | 157 | 0.420 |
Why?
| | Cell Line, Tumor | 9 | 2025 | 3550 | 0.420 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2026 | 66 | 0.390 |
Why?
| | DNA Repair | 2 | 2024 | 256 | 0.320 |
Why?
| | Humans | 25 | 2026 | 144957 | 0.290 |
Why?
| | Antineoplastic Agents | 2 | 2022 | 2197 | 0.290 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 683 | 0.280 |
Why?
| | Epigenesis, Genetic | 2 | 2025 | 685 | 0.270 |
Why?
| | Mice | 11 | 2026 | 18365 | 0.270 |
Why?
| | Child | 7 | 2024 | 22657 | 0.260 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2025 | 70 | 0.260 |
Why?
| | CRISPR-Cas Systems | 2 | 2025 | 170 | 0.260 |
Why?
| | Tumor Cells, Cultured | 2 | 2025 | 919 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 9 | 1 | 2025 | 18 | 0.230 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Cyclin-Dependent Kinase 8 | 1 | 2025 | 50 | 0.230 |
Why?
| | Gene Fusion | 1 | 2025 | 29 | 0.220 |
Why?
| | SMARCB1 Protein | 1 | 2025 | 34 | 0.220 |
Why?
| | Sirtuin 2 | 1 | 2025 | 27 | 0.220 |
Why?
| | Cell Proliferation | 4 | 2025 | 2499 | 0.220 |
Why?
| | Infratentorial Neoplasms | 1 | 2025 | 71 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2025 | 193 | 0.210 |
Why?
| | RNA Polymerase II | 2 | 2025 | 351 | 0.210 |
Why?
| | Gene Rearrangement | 1 | 2025 | 155 | 0.210 |
Why?
| | Child, Preschool | 5 | 2021 | 11799 | 0.200 |
Why?
| | Rhabdoid Tumor | 1 | 2025 | 103 | 0.200 |
Why?
| | Phagocytosis | 1 | 2025 | 299 | 0.200 |
Why?
| | Ependymoma | 1 | 2025 | 176 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 39 | 0.190 |
Why?
| | Animals | 11 | 2026 | 38109 | 0.190 |
Why?
| | Epigenomics | 2 | 2020 | 114 | 0.190 |
Why?
| | Protein Biosynthesis | 1 | 2025 | 458 | 0.190 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 59 | 0.190 |
Why?
| | Brain Stem | 1 | 2023 | 96 | 0.180 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 550 | 0.170 |
Why?
| | Apoptosis | 3 | 2025 | 2430 | 0.170 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2023 | 226 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2021 | 307 | 0.160 |
Why?
| | Nuclear Proteins | 1 | 2025 | 749 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 883 | 0.160 |
Why?
| | Attitude to Death | 1 | 2020 | 73 | 0.150 |
Why?
| | Narration | 1 | 2020 | 75 | 0.150 |
Why?
| | Female | 9 | 2025 | 78376 | 0.140 |
Why?
| | Necrosis | 1 | 2019 | 244 | 0.140 |
Why?
| | Point Mutation | 1 | 2019 | 243 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1524 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1511 | 0.130 |
Why?
| | Rhabdomyoma | 1 | 2017 | 7 | 0.130 |
Why?
| | Angiomyolipoma | 1 | 2017 | 21 | 0.130 |
Why?
| | Dexamethasone | 1 | 2019 | 372 | 0.130 |
Why?
| | Heart Neoplasms | 1 | 2017 | 56 | 0.120 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 2015 | 17 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3869 | 0.110 |
Why?
| | Glucocorticoids | 1 | 2019 | 535 | 0.110 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 321 | 0.110 |
Why?
| | Feasibility Studies | 1 | 2019 | 1095 | 0.110 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 695 | 0.110 |
Why?
| | Stem Cell Transplantation | 1 | 2015 | 191 | 0.100 |
Why?
| | Pilot Projects | 1 | 2019 | 1890 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1958 | 0.090 |
Why?
| | Kidney Neoplasms | 1 | 2017 | 412 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1048 | 0.090 |
Why?
| | Infant | 2 | 2017 | 10039 | 0.090 |
Why?
| | Cell Differentiation | 3 | 2026 | 2050 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2609 | 0.090 |
Why?
| | Male | 5 | 2021 | 72406 | 0.090 |
Why?
| | Phenotype | 1 | 2019 | 3164 | 0.080 |
Why?
| | Skin Neoplasms | 1 | 2017 | 847 | 0.080 |
Why?
| | Aging | 1 | 2020 | 1966 | 0.080 |
Why?
| | Neoplasms | 1 | 2025 | 2884 | 0.070 |
Why?
| | Brain | 1 | 2020 | 2941 | 0.070 |
Why?
| | Polycomb-Group Proteins | 1 | 2026 | 36 | 0.060 |
Why?
| | Methylation | 1 | 2026 | 242 | 0.060 |
Why?
| | Heterochromatin | 1 | 2026 | 67 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 42 | 0.060 |
Why?
| | Pluripotent Stem Cells | 1 | 2026 | 84 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2025 | 37 | 0.060 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2026 | 82 | 0.060 |
Why?
| | Radiation Tolerance | 1 | 2025 | 103 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2025 | 33 | 0.050 |
Why?
| | Formaldehyde | 1 | 2025 | 66 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 1141 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2025 | 323 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2642 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2025 | 17101 | 0.050 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 451 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 359 | 0.050 |
Why?
| | Cell Cycle Proteins | 1 | 2026 | 629 | 0.040 |
Why?
| | Radiation, Ionizing | 1 | 2022 | 87 | 0.040 |
Why?
| | NF-kappa B | 1 | 2025 | 662 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 241 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 280 | 0.040 |
Why?
| | Adolescent | 1 | 2019 | 22453 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 621 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 302 | 0.030 |
Why?
| | Sulfonamides | 1 | 2022 | 581 | 0.030 |
Why?
| | Signal Transduction | 1 | 2025 | 5233 | 0.020 |
Why?
|
|
Dahl's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|